title: A meta-analysis of HIF-1α and esophageal squamous cell carcinoma (ESCC) risk.
abstract: To investigate the correlation of hypoxia-inducible factor-1α (HIF-1α) expression with clinical prognosis and efficacy of radiochemotherapy in esophageal squamous cell carcinoma (ESCC). Studies assessing the clinical or prognostic significance of HIF-1α expression in ESCC published prior to December 2011 were selected by searching PubMed, EMBASE, Cochrane Library, and (China National Knowledge Infrastructure) CNKI. A meta-analysis was performed to clarify the impact of HIF-1α expression on clinicopathological parameters or survival in ESCC. A total of 16 studies met the inclusion criteria, which included 1261 patients with ESCC. Accordingly, the level of HIF-1α expression in esophageal tissues of patients with ESCC was significantly higher than that in normal patients (odds ratio, OR = 33.111, 95 % confidence interval, CI = 11.912-92.040). The expression of HIF-1α correlated with the depth of invasion (OR = 1.701, 95 % CI = 1.076-4.705), clinical TNM stage (OR = 2.160, 95%CI = 1.516-3.077), as well as lymph node metastasis (OR = 2.393, 95 % CI = 1.319-4.344), regardless of differentiation grading (OR = 1.185, 95 % CI = 0.859-1.635). Furthermore, there was a significant association of increased HIF-1α expression with poorer radiochemotherapy outcomes, 2-year overall survival (OR = 0.219, 95 % CI = 0.104-0.461) and survival (OR = 0.320, 95 % CI = 0.115-0.887, P < 0.05) in patients with ESCC. In addition, HIF-1α expression correlated with VEGF expression in the ESCCs (OR = 4.635, 95%CI = 2.591-8.292). Increased expression of HIF-1α plays an important role in the malignant biology of ESCC resulting in significantly poorer radiochemotherapy outcomes and 2-year overall survival. HIF-1α expression may be a prognostic factor, as well as a potential target for therapy in patients with ESCC.
authors: Department of Chemoradiology, People's Hospital Affiliated to Hebei United University, Tangshan, 063000,, Hebei Province, China.
authors: Guogui
authors: G
authors: Sun
authors: Wanning
authors: W
authors: Hu
authors: Yifang
authors: Y
authors: Lu
authors: Yadi
authors: Y
authors: Wang
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000473:pathology; D004938:Esophageal Neoplasms / Q000378:metabolism* / Q000473:pathology; D000077277:Esophageal Squamous Cell Carcinoma; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000378:metabolism*; D016017:Odds Ratio; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A
references: Hepatogastroenterology. 2011 Mar-Apr;58(106):426-31
references: 21661408
references: Asian Pac J Cancer Prev. 2011;12(10):2623-7
references: 22320964
references: World J Gastroenterol. 2010 Sep 7;16(33):4210-20
references: 20806441
references: Dis Esophagus. 2012 Aug;25(6):520-6
references: 22098104
references: Acta Physiol Hung. 2009 Mar;96(1):19-28
references: 19264039
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: Br J Cancer. 2003 Sep 15;89(6):1042-7
references: 12966423
references: Nature. 2011 May 19;473(7347):298-307
references: 21593862
references: Int J Cancer. 2012 Dec 15;131(12):2785-94
references: 22505354
references: Anticancer Res. 2011 Jun;31(6):2351-9
references: 21737664
references: Br J Haematol. 2008 May;141(3):325-34
references: 18410568
references: Lancet Oncol. 2007 Mar;8(3):226-34
references: 17329193
references: Am J Pathol. 2000 Aug;157(2):411-21
references: 10934146
references: Mol Carcinog. 2010 Sep;49(9):805-9
references: 20572162
references: Pathol Int. 2009 Jan;59(1):19-27
references: 19121088
references: FASEB J. 2012 Jun;26(6):2620-30
references: 22415309
references: Cancer. 2004 Jan 1;100(1):201-10
references: 14692041
references: World J Gastroenterol. 2010 Dec 21;16(47):6020-5
references: 21157980
references: Cell. 2011 Oct 14;147(2):275-92
references: 22000009
references: Oncogene. 2003 May 22;22(21):3213-20
references: 12761491
references: Cancer Res. 2006 Mar 15;66(6):3197-204
references: 16540671
references: Nature. 2008 Feb 21;451(7181):1008-12
references: 18288196
references: Eur J Cancer. 2004 Aug;40(12):1904-12
references: 15288294
references: Zhonghua Zhong Liu Za Zhi. 2007 Sep;29(9):689-92
references: 18246800
references: N Engl J Med. 2003 Dec 4;349(23):2241-52
references: 14657432
references: Dis Markers. 2008;25(3):141-8
references: 19096126
references: Neoplasia. 2006 Nov;8(11):889-95
references: 17132220
references: Zhonghua Yi Xue Za Zhi. 2007 Jul 3;87(25):1783-5
references: 17919389
references: Int J Cancer. 2004 Jul 20;110(6):838-44
references: 15170665
references: Tohoku J Exp Med. 2011;223(2):137-44
references: 21304218
references: Cancer Cell. 2004 Nov;6(5):485-95
references: 15542432
references: Zhonghua Yi Xue Za Zhi. 2008 Sep 16;88(35):2465-9
references: 19080625
references: Cancer Sci. 2005 Mar;96(3):176-82
references: 15771621
references: Eur J Cancer. 2010 Apr;46(6):1159-69
references: 20185296